Citations

Showing 10 of 108119 citations.

Quantitative electroencephalography features of dysexecutive Alzheimer's disease
Varatharajah, Yogatheesan , Barnard, Leland R , Allen, Kay S., Li, Wentao , Brinkmann, Benjamin H. , Worrell, Gregory A. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.051939 Get It

AbstractBackgroundProgressive dysexecutive syndrome (dAD) is an atypical presentation of early onset Alzheimer’s disease (AD) with increased frontal and parietal region hypometabolism on FDG‐PET imaging compared to classic amnestic AD. We compared electroencephalogram (EEG) and FDG‐PET in dAD patients to determine if there was a correlation between EEG spectral activity and standard uptake value ratios (SUVR) in those regions.MethodFDG‐PET and resting state scalp EEG were obtained on AD‐biomarker confirmed, behavioral neurologist diagnosed cases of dAD (n = 11). We isolated awake‐eyes‐closed segments (mean duration: 113s, median:118s, range: 58‐138s) of each EEG and calculated the relative power of delta, theta, alpha, beta, and gamma bands within a wideband of 0.5‐40 Hz. In bilateral frontal and parietal regions, we averaged select channels across 6 to 14 10‐second windows per subject (fig.1). We evaluated the correlation between relative band powers and SUVRs of the regions by linear regression analysis.ResultThere is a strong negative correlation (R2 = 0.54, p < 0.01) between alpha band relative power and SUVR in bilateral frontal regions (fig 2). Delta band relative power showed a strong positive correlation (R2 = 0.54, p < 0.05) with SUVR in the left frontal region. A positive trend was noted in the delta band in the right frontal region but did not reach statistical significance. Beta band relative power was negatively correlated with frontal region SUVR bilaterally, but only the left side reached statistical significance. These findings remained significant after multiple comparisons correction. No statistically significant correlations were noted in the parietal regions. Exploratory analysis revealed negative correlations between alpha bands and temporal region SUVRs bilaterally.ConclusionIn this small sample of selected individuals with dysexecutive AD, we report a strong correlation between EEG relative spectral power and PET regional SUVR in multiple EEG frequency bands and brain regions. In the bilateral frontal regions, slower delta frequencies and faster alpha and beta frequencies were associated with lower FDG‐PET signal. Future studies are needed to determine if this spectral power pattern and other EEG properties of dAD differ from other clinical dementia phenotypes and its clinical significance.
Heterogeneity in imaging‐based spread of tau and atrophy in atypical AD
Whitwell, Jennifer L.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.050825 Get It

AbstractBackgroundDifferent clinical phenotypes of atypical AD are each associated with characteristic patterns of neurodegeneration and tau deposition on PET. However, longitudinal patterns of tau accumulation and atrophy dissociate and there is significant subject‐level heterogeneity in patterns of progression. We investigate the degree to which heterogeneity in tau progression and atrophy is related to age, apolipoprotein (APOE) genotype and clinical progression.MethodThe Neurodegenerative Research Group (NRG) recruited 138 atypical AD patients (posterior cortical atrophy [PCA] = 57, logopenic progressive aphasia [LPA] = 81), of which 57 underwent longitudinal 3T head MRI and [18F]flortaucipir PET. Region‐of‐interest and voxel‐level analyses were utilized to assess relationships between rates of both atrophy and flortaucipir accumulation with age and APOE ε4 genotype. Principle component analysis using 12 different cognitive tests was used to assess patterns of clinical decline, with the principle components correlated to neuroimaging.ResultFastest rates of tau accumulation were observed in the frontal lobes in PCA and LPA, while fastest rates of atrophy were observed in occipital lobe in PCA and left temporoparietal lobe in LPA. Cortical rates of tau accumulation, particularly in the frontal lobe, were faster in younger patients and in APOE ε4 non‐carriers within LPA and PCA. Spatial patterns of tau accumulation were similar in both carriers and non‐carriers. Cortical rates of atrophy, particularly in parietal regions, were faster in younger patients in PCA and LPA, and in APOE ε4 non‐carriers. Conversely, rates of medial temporal atrophy were faster in older patients and APOE ε4 carriers. Increased rates of tau accumulation across the cortex, but particularly in frontal regions, corresponded to greater severity of clinical decline across tests over time.ConclusionRates of tau accumulation and atrophy are both influenced by age and APOE genotype in atypical AD, but with different regional associations observed for each modality. These findings highlight heterogeneity present in neuroimaging signatures of atypical AD beyond clinical phenotype.
CSF and blood plasma mass spectrometry measures of Aβ, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer’s disease
Barthélemy, Nicolas R. , Bollinger, James G., Fagan, Anne M. , Mawuenyega, Kwasi G., Ovod, Vitaliy , Budelier, Melissa M. , Petersen, Ronald C. , Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Mike, Xiong, Chengjie , Bateman, Randall J. , Benzinger, Tammie L.S. , Gordon, Brian A. , Hansson, Oskar , Holtzman, David M. , Horie, Kanta , Li, Melody , Masters, Colin L. , McDade, Eric , Morris, John C. , He, Chloe , Mielke, Michelle M. , Sato, Chihiro , Schindler, Suzanne E.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.050711 Get It

AbstractBackgroundRecent advances in the development of novel Alzheimer’s disease (AD) measures of amyloid, tau, and neurodegeneration in cerebrospinal fluid (CSF) and blood have enabled a better understanding of the links between amyloid‐beta (Aβ), tau species and neurodegeneration in the brain, CSF, and blood. The discoveries of novel tau species in CSF and blood, including specific phospho‐tau (p‐tau) and truncated species containing the microtubule binding region of tau (MTBR‐tau) which aggregates in tau tangles, have greatly expanded our understanding of tau biology and tau target development. The longitudinal Aβ, tau, and neurofilament light chain (NfL) changes previously measured in CSF are now being measured accurately in blood, enabling interpretation and understanding of AD progression in much larger and more robust populations.MethodWe analyzed longitudinal CSF and/or blood plasma mass spectrometry measures of Aβ42/Aβ40, multiple p‐tau species (including p‐tau217, 231, 181, 205, etc.), total tau, MTBR‐tau (e.g., MTBR‐tau243, MTBR‐tau299, and MTBR‐tau354), and NfL in sporadic AD and dominantly inherited AD cohorts. Mass spectrometry results were compared to amyloid and tau aggregation measures by Positron Emission Tomography (PET) scans and clinical and cognitive measures in local and international clinical cohorts including ADNI, AIBL, BioFINDER, Mayo Clinic, the Knight ADRC, and the DIAN.ResultThe longitudinal results indicate that a pathophysiological cascade of events begin with altered CSF and blood plasma Aβ42/Aβ40 ratio, followed by increases in amyloid plaques as measured by amyloid PET, associated with increased phosphorylation of specific CSF tau species (e.g., p‐tau217, p‐tau181, etc.), before increases in p‐tau205, NfL, total tau concentrations, hypometabolism, and atrophy. Finally, some species of MTBR‐tau increase before or with tau aggregation by tau PET and onset of clinical symptoms and correlate with longitudinal tau aggregation and clinical progression.ConclusionThese findings indicate that CSF and blood plasma Aβ, p‐tau, MTBR‐tau and NfL measures are highly precise biomarkers of brain amyloidosis, tauopathy, and neurodegeneration and can accurately identify stages of preclinical and clinical AD.
Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application
Benedet, Andréa Lessa , Gauthier, Serge , Petersen, Ronald C. , Thambisetty, Madhav , Varma, Vijay R. , Resnick, Susan M. , Villeneuve, Sylvia , Galasko, Doug, Fauria, Karine , Blennow, Kaj , Ashton, Nicholas J. , Karikari, Thomas K. , Lantero‐Rodriguez, Juan , Snellman, Anniina , Pascoal, Tharick Ali , Rosa-Neto, Pedro , Jack, Clifford R. , Mielke, Michelle M. , Chatterjee, Pratishtha , Martins, Ralph N. , Fox, Nick C. , O’Connor, Antoinette , Vrillon, Agathe , Paquet, Claire , Poirier, Judes , Milà‐Alomà, Marta , Minguillón, Carolina , Suárez‐Calvet, Marc , Vanmechelen, Eugeen , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.056186 Get It

AbstractBackgroundBlood phosphorylated tau (p‐tau) has proven to be the primary candidate as an accessible and scalable biomarker for Alzheimer’s disease (AD). Both p‐tau181 and p‐tau217 are highly accurate to detect AD within dementia cases. Our recent work in cerebrospinal fluid, however, indicates p‐tau231 to be associated to incipient AD pathology. In light of this, we developed a Single molecule array (Simoa) to detect plasma p‐tau231 and assessed its performance in multiple domains, specifically, its ability to detect preclinical AD.MethodIn all cohorts, plasma p‐tau231 was quantified using an in‐house Simoa method developed at the Clinical Neurochemistry Laboratory, Gothenburg University, Sweden. Data presented in this study are samples acquired from Translational Biomarkers of Aging and Dementia (TRIAD, n=503), King’s College London (n=55), Mayo Clinic Study of Aging (n=145), KARVIAH (n=140), Baltimore Longitudinal Study of Aging (n=430), University College London (n=70), Paris University (n=213), PREVENT‐AD (n=257), University of California (n=309) and ALFA+ (n=385).ResultIn the TRIAD cohort, plasma p‐tau231 demonstrated high accuracy in determining AD from young individuals (AUC=0.95), Aβ‐ elderly (AUC=0.92), Aβ‐ MCI (AUC=0.88) and other neurodegenerative disorders (AUC=0.92). In an autopsy study, plasma p‐tau231 could detect neuropathologically confirmed AD amongst dementia cases (AUC=0.99). In comparing healthy elderly Aβ‐ and Aβ+ individuals, p‐tau231 predicted preclinical Aβ pathology (AUC=0.83). Furthermore, inflection points of the weighted regression curves demonstrate that increases in plasma p‐tau231 occur before plasma p‐tau181 as a function of Aβ deposition load. Plasma p‐tau231 data from additional cohorts will focus on cross‐sectional and longitudinal preclinical datasets. In addition, further data will show the performance of p‐tau231 in symptomatic and presymptomatic PSEN1/APP mutation carriers, memory clinic cohorts, longitudinal neuropathology confirmed and acute neurological injury.ConclusionPlasma p‐tau231 is a new biomarker specific for AD pathology and at higher concentrations relative to p‐tau181 and p‐tau217. Our initial results indicate that plasma p‐tau231 is equivalent to p‐tau181 in diagnostic utility but has greater potential as a biomarker to monitor emerging Aβ pathology. This presentation will give an overview of novel cross‐sectional and longitudinal plasma p‐tau231 data, in more than 3000 individuals, that encompasses the AD continuum, familial AD and other neurological conditions.
Plasma transcript profiling identifies significant differentially expressed genes and expression of quantitative trait loci in African Americans
Carrasquillo, Minerva M. , Jin, Jianli, Reddy, Joseph S. , Lincoln, Sarah, Ho, Charlotte C.G. , Malphrus, Kimberly G., Nguyen, Thuy , Greig‐Custo, Maria T., Lucas, John A. , Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Jin, Jianli, Crook, Julia E.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.055643 Get It

AbstractBackgroundAfrican Americans (AA) remain underrepresented in Alzheimer’s disease (AD) research, despite the prevalence of AD being ∼2X higher in this population compared to non‐Hispanic whites. To address this disparity, our group has established the Florida Consortium for African American Alzheimer’s Disease Studies (FCA3DS), focusing primarily on the identification of genetic risk factors and novel plasma biomarkers.MethodUtilizing plasma samples from FCA3DS AD cases (n=158) and cognitively unimpaired elderly controls (n=272), we have performed differential gene expression (DEG) and expression quantitative trait locus (eQTL) analyses on 50 transcripts measured with a custom NanoString® panel that we have designed to measure transcript levels in plasma of genes relevant to AD. Transcript counts were determined using the NanoString® nCounter system, following manufacturer’s protocols. Transcript counts from 43 of the 50 customs assays passed pre‐established quality control thresholds and were utilized for the DEG and eQTL analyses. Our published FCA3DS whole exome sequence (WES) data was utilized for the eQTL analyses. Linear mixed models adjusted for relevant biological and technical covariates were implemented with the lme4 package in R software (v3.6.2) for the DEG and eQTL analyses.ResultAn association with higher plasma CLU in controls compared to AD remained significant after Bonferroni correction for the 43 transcripts tested. The eQTL analysis revealed significant association (FDR q‐value<0.05) with 105 WES variants in cis with 22 of 43 genes tested, including variants in genes previously associated with AD risk in AA. ConclusionThe results from this AA plasma eQTL analysis revealed ABCA7 variants that are significantly associated with lower plasma ABCA7 transcript levels. One of the significant plasma ABCA7 eQTLs was previously shown by our group to be associated with increased AD risk in AA, suggesting that this may be a functional eQTL underlying the risk of AD in AA. The association of higher levels of CLU transcript in plasma from controls compared to AD is in line with results published by others which showed that higher baseline concentration of clusterin protein in plasma was associated with slower rates of brain atrophy. These results support plasma transcripts as novel endophenotypes in AD biomarker studies.
Disparities in dementia and AD biomarkers in the ARIC study: The important contribution of social determinants of health
Wong, Dean F. , Gottesman, Rebecca F. , Schneider, Andrea L.C. , Rawlings, Andreea M. , Power, Melinda C. , Walker, Keenan A. , Wruck, Lisa , Jack, Clifford R. , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.052844 Get It

AbstractBackgroundDementia disproportionately impacts people of color in the U.S.. Whether these disparities are due to differences in vascular risk factors, cognitive reserve, or AD pathophysiology remains unclear.MethodBlack and White participants from four U.S. communities were recruited into the Atherosclerosis Risk in Communities (ARIC) study at ages 45‐64. Vascular risk factors were evaluated in midlife and at multiple visits over 30+ years, as were markers of cognitive reserve, with expert classification of dementia. In participants with brain MRI, brain volumes were evaluated in association with dementia. In nondemented participants in the ARIC‐PET ancillary study, florbetapir PET scans were used to quantify brain cortical amyloid; differences in levels by race, vascular risk factors, and white matter hyperintensities (WMH) were evaluated.ResultIn 15744 ARIC participants, dementia was more common in Black vs White participants. Although midlife vascular risk factors were related to dementia, the impact of these risk factors on dementia risk and cortical volumes didn’t differ by race. Lower education was nonsignificantly more strongly associated with dementia in Blacks vs Whites, and an APOE e4 allele was more strongly associated with dementia in Whites. In ARIC‐PET (N=322), vascular risk factors from midlife were associated with PET amyloid, without similar associations for late‐life risk factors; these associations did not significantly differ by race. WMH volume was more strongly associated (cross‐sectionally) with PET amyloid in Blacks vs Whites, but differences were not statistically significantly different. Finally, Blacks had an over two‐fold increased odds of elevated florbetapir PET vs Whites, independent of vascular risk factors, demographics, WMH volume, cognitive status, and APOE genotype.ConclusionConsideration of racial disparities in dementia should consider vascular risk, cognitive reserve, and social determinants of health, across the life course. Vascular risk factors do not appear to differentially impact dementia risk or brain amyloid in Blacks vs Whites, but the greater prevalence of these risk factors in Blacks must be considered. Although the A/T/N framework may clarify underlying biology contributing to Alzheimer’s disease, inclusion of these additional factors is needed to understand and reduce racial disparities in dementia rates.
Objective home sleep profiles differentiate Alzheimer disease from α‐synucleinopathies
Levendowski, Daniel J. , Walsh, Christine M. , Salat, David H. , Hamilton, Joanne M., Ruoff, Leslie, Payne, Sarah, Lee‐Iannotti, Joyce , Westbrook, Philip R., Mazeika, Gandis, Boeve, Bradley F. , Neylan, Thomas C. , Tsuang, Debby W. , Shprecher, David , Berka, Chris , Louis, Erik K. St.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.052238 Get It

AbstractBackgroundNeurodegenerative disease (NDD) is associated with sleep disturbances, including decreased stage N3 and REM sleep and reduced spindle activity. Further, supine sleep position may impact NDD risk by altering glymphatic clearance. This study evaluated conventional and exploratory sleep metrics in the differentiation of subjects with normal cognition (NC) and patients with Alzheimer’s disease dementia (AD) and alpha‐synucleinopathies (α‐Syn).MethodHome sleep data were acquired across multiple study sites using the self‐applied Sleep ProfilerTM, including 44 NC subjects (age=69+5.0), 22 patients diagnosed with AD (age=75+7.1) and 25 with α‐Syn (Parkinson’s disease=14, Parkinson’s disease with Dementia or Dementia with Lewy Bodies=11; age=69+6.9). Recordings were auto‐staged and technically reviewed, with 86% of the records having two‐night averages. Logistic regression and Mann‐Whitney U tests were used to characterize group differences based on age, conventional sleep metrics (i.e., sleep efficiency, sleep onset (SO), awakenings, percent of sleep time (%) in REM,N1, N2 and N3, and sleep spindles) and exploratory sleep measures [i.e., % supine, % Light N2 (L2=N2 epochs absent of spindles with K‐complexes and/or alpha or EMG (>40 Hz) intrusion), % NREM sleep with hypertonia (NRSH=>4 consecutive epochs with persistently elevated EMG power relative to delta and theta power) and % atypical N3 (AN3=epochs staged N3 with low theta and sigma power relative to delta, alpha, beta and EMG)].ResultAD were older than both NC and α‐Syn patients (p<0.005). Both AD and α‐Syn had lower %REM and greater %supine than NC (p<0.005), and %NRSH was greater in α‐Syn than NC or AD (p<0.005). Based on logistic regression, AD was differentiated from NC based on age, %REM, %L2 (p<0.05) and %supine (p=0.06). α‐Syn was distinguished from NC using both conventional (%N3 and SO, p<0.05) and exploratory sleep metric (%AN3 and %NRSH, p<0.05; %supine, p=0.06). Age (p=0.05) and %NRSH (p<0.01) were the only metrics that differentiated α‐Syn from AD.ConclusionObjective home sleep profiles hold promise for differentiating NDD patients from NC. The sleep metrics that provided the greatest distinction between NDD and NC were %REM, %supine and NRSH, while only NRSH distinguished AD from α‐Syn patients. Further confirmatory studies are underway.
Factors associated with levels of plasma markers of amyloid pathology and neurodegeneration in a population‐based sample
Syrjanen, Jeremy A. , Campbell, Michelle R. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Algeciras‐Schimnich, Alicia , Vemuri, Prashanthi , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.051720 Get It

AbstractBackgroundBlood‐based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect these plasma marker levels for accurate clinical interpretation. Herein we examined factors associated with plasma Ab42, Ab40, neurofilament light (NfL), total tau (T‐tau), and the ratio of Ab42 to Ab40 (Ab42/40).MethodThe plasma markers were measured for 996 participants (859 cognitively unimpaired [CU], 133 mild cognitive impairment [MCI], 4 dementia) from the Mayo Clinic Study of Aging (MCSA), aged 51 to 95 years. The Quanterix Simoa® HD‐1 analyzer was employed to measure the plasma markers using the Simoa® Neurology 3‐Plex A (N3PA) (T‐tau, Ab42, Ab40) (catalog #101995) and the Simoa® NF‐light (catalog #103180). All other data was collected during in‐person MCSA visits or abstracted from the medical record. Statistical significance was determined using an alpha level of 0.05.ResultAmong CU, all of the plasma markers showed correlation with age. T‐tau (Spearman’s rho = 0.113, p<0.001) showed the weakest correlation and NfL (rho = 0.695, p<0.001) had the strongest. Women had higher levels of T‐tau (Median women: 2.782 vs. 2.390, p<0.001) and lower Ab42/40 (0.033 vs. 0.035, p=0.024) compared to men. In linear regression models predicting z‐scored plasma markers and adjusted for age and sex, several statistically significant predictors were found. For example, higher Charlson comorbidity index and chronic kidney disease were associated with higher levels of all markers; slower gait speed was associated with higher levels for all but Ab42/40 where no relationship was seen. A higher BMI was associated with higher levels of Ab42, Ab40, and T‐tau whereas NfL tended to be lower with increased BMI. Among participants with MCI or dementia, the relationship between gait speed or chronic kidney disease with NfL and T‐tau strengthened considerably.ConclusionMultiple variables affect plasma markers of amyloid pathology and neurodegeneration among CU in the general population. Some relationships differed among MCI and dementia participants. Incorporating this information is critical for accurate interpretation of the marker levels and for the development of reference ranges.
Alzheimer’s disease CSF biomarker assays: Impact of methodology changes in clinical practice
Campbell, Michelle R. , Kian, Susan Ashrafzadeh, Petersen, Ronald C. , Bornhorst, Joshua , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.051426 Get It

AbstractBackgroundDecreased amyloid β1‐42 (Aβ42) and increased tau (t‐Tau and p‐Tau) concentrations in cerebrospinal fluid (CSF) reflect the pathological changes of Alzheimer’s disease (AD) and aid in the diagnosis of AD dementia. In the United States, the ADmark® assay has been almost exclusively used for the measurement of these biomarkers in clinical practice. Recently, our institution switched from the ADmark® assay to the Roche Elecsys assays. The goal of this study was to determine if differences exist between these methods in classification of patients as having changes indicative of AD pathology.MethodPatients undergoing ADMark® testing (n= 73) were recruited to participate in this IRB‐approved study. Two simultaneous CSF aliquots were obtained. For ADMark®, 2.0mL were collected into a 5mL polypropylene (PP) tube and shipped frozen to Athena Diagnostics per collection instructions for testing (Innotest® immunoassays for Aβ42, t‐Tau, and p‐Tau). For the Roche Elecsys assays (Aβ42, t‐Tau, and p‐Tau), 2.0mL were collected into a 2.5mL low bind PP tube, frozen, and then tested at Mayo Clinic Laboratories. Comparative analysis was performed between the two testing methodologies and to clinical findings.ResultOverall concordance between the ADMark® Aβ42/t‐Tau index (ATI) and Roche p‐Tau/Aβ42 was 89% with 8 (11%) discrepant cases. Four cases were classified as normal by the Roche p‐Tau/Aβ42 but borderline (n=3) or abnormal (n=1) by ADMark® ATI. Four cases were classified as abnormal by the Roche p‐Tau/Aβ42 and borderline by ADMark® ATI. In these cases, the normal Roche p‐Tau/Aβ42 result was most consistent with clinical diagnosis. When compared to clinical diagnosis, cases with clinical suspicion of AD dementia were abnormal in 84% and 92% of cases with the ADMark® ATI and the Roche p‐Tau/Aβ42, respectively. In cases without clinical suspicion of AD dementia, results were abnormal in 19% and 21% of cases with the ADMark® ATI and the Roche p‐Tau/Aβ42, respectively. There were 2 cases with clinical suspicion of AD dementia and 5 cases without suspicion of AD dementia that were classified as borderline by ADMark® ATI.ConclusionRoche p‐Tau/Aβ42 showed comparable performance to ADMark® ATI when correlating results to clinical diagnosis of AD dementia.
EEG biomarkers differentiate Lewy body dementia from Alzheimer’s disease
Karić, Marija Stevanović , Waninger, Shani, McConnell, Marissa, Poole, Jared , Rupp, Greg , Hamilton, Joanne M., Meghdadi, Amir H. , Richard, Christian , Boeve, Bradley F. , Louis, Erik K. St. , Berka, Chris

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.051386 Get It

AbstractBackgroundResting state electroencephalography (rsEEG) is a neurophysiologic Alzheimer disease (AD) and alpha‐synucleinopathy (dementia with Lewy body (DLB) and Parkinson disease (PDD)) biomarker [1]–[5]. Background slowing (increased low frequency power, dominant rhythm (DR) slowing) is frequent in AD and DLB, more so in DLB. We sought to identify distinguishing rsEEG signatures between DLB and AD.MethodParticipants included dementia patients [AD (n=26), DLB (n=12), PD (PDD; n=5)] and controls (HC; n=56). 20‐channel rsEEG was collected in eyes‐closed/eyes‐open conditions (5‐min each). Power spectral densities and coherences were measured using established methods [6]. Individual rsEEG power (delta, 1‐3 Hz; theta, 3‐7 Hz; alpha, 8‐13 Hz), theta/alpha ratio (TAR), dominant rhythm (DR), and DR frequency domain prominence were measured and averaged across groups, and effect sizes were determined and compared using Hedges g.ResultAD, DLB, and PDD groups exhibited increased low frequency (delta‐theta, 1‐5 Hz) power and TAR compared to controls (p<4x10‐4), with higher effect sizes in the DLB and PDD groups compared to AD. DR frequency was also decreased in all patient groups (DLB>PDD>AD) compared to controls (p=3x10‐9, p=3x10‐5, p=4x10‐4).AD alpha power and DR frequency domain prominence were reduced compared to controls and PDD/DLB groups (p<0.003). Both AD patients and controls had comparable posterior power distribution predominance of DR, while DLB power of DR was more anteriorly distributed. Compared to controls, delta coherence was higher in AD, but lower in DLB. Delta power was positively correlated with cognitive fluctuation (CAF) in DLB (r(8)=+0.67, p=0.03), while negatively correlated with MMSE in AD (r(24)=‐0.64, p=10‐5).ConclusionDLB and AD had both common and distinct rsEEG signatures. Both had DR slowing and background slowing that was more severe in DLB than AD. Distinctive DLB findings included reduced posterior DR spatial dominance and decreased delta coherence. Conversely, distinct AD features were increased delta coherence, decreased alpha power, and decreased DR frequency prominence. Finally, the DLB and PDD groups had a similar magnitude of DR slowing, consistent with posteriorly dominant functional impairment in synucleinopathy reflected by corresponding regional rsEEG slowing, although future longitudinal prospective sequential rsEEG analyses are necessary to confirm these findings.